Clinical Trial Update: Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres [Phase 2]

View source ↗

Summary

Phase 2 trial investigating lanreotide in metastatic gastrointestinal neuroendocrine tumors undergoing liver-directed radioembolization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Neoplasm
• Neuroendocrine Tumor

Drugs mentioned

• Lanreotide (lanreotide)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Neuroendocrine Tumors, Gastrointestinal Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2023-07-27